These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

713 related articles for article (PubMed ID: 29260466)

  • 1. Targeting Neuroinflammation to Treat Alzheimer's Disease.
    Ardura-Fabregat A; Boddeke EWGM; Boza-Serrano A; Brioschi S; Castro-Gomez S; Ceyzériat K; Dansokho C; Dierkes T; Gelders G; Heneka MT; Hoeijmakers L; Hoffmann A; Iaccarino L; Jahnert S; Kuhbandner K; Landreth G; Lonnemann N; Löschmann PA; McManus RM; Paulus A; Reemst K; Sanchez-Caro JM; Tiberi A; Van der Perren A; Vautheny A; Venegas C; Webers A; Weydt P; Wijasa TS; Xiang X; Yang Y
    CNS Drugs; 2017 Dec; 31(12):1057-1082. PubMed ID: 29260466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Innate immune system and inflammation in Alzheimer's disease: from pathogenesis to treatment.
    Serpente M; Bonsi R; Scarpini E; Galimberti D
    Neuroimmunomodulation; 2014; 21(2-3):79-87. PubMed ID: 24557039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-Neuroinflammatory Potential of Polyphenols by Inhibiting NF-κB to Halt Alzheimer's Disease.
    Uddin MS; Hasana S; Ahmad J; Hossain MF; Rahman MM; Behl T; Rauf A; Ahmad A; Hafeez A; Perveen A; Ashraf GM
    Curr Pharm Des; 2021; 27(3):402-414. PubMed ID: 33213314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inflammation in Alzheimer's disease: amyloid-beta oligomers trigger innate immunity defence via pattern recognition receptors.
    Salminen A; Ojala J; Kauppinen A; Kaarniranta K; Suuronen T
    Prog Neurobiol; 2009 Feb; 87(3):181-94. PubMed ID: 19388207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Active immunization against complement factor C5a: a new therapeutic approach for Alzheimer's disease.
    Landlinger C; Oberleitner L; Gruber P; Noiges B; Yatsyk K; Santic R; Mandler M; Staffler G
    J Neuroinflammation; 2015 Aug; 12():150. PubMed ID: 26275910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inflammation and Alzheimer's Disease: Mechanisms and Therapeutic Implications by Natural Products.
    Rather MA; Khan A; Alshahrani S; Rashid H; Qadri M; Rashid S; Alsaffar RM; Kamal MA; Rehman MU
    Mediators Inflamm; 2021; 2021():9982954. PubMed ID: 34381308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Innate immunity in Alzheimer's disease.
    Heneka MT; Golenbock DT; Latz E
    Nat Immunol; 2015 Mar; 16(3):229-36. PubMed ID: 25689443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Innate Immunity Fights Alzheimer's Disease.
    Guillot-Sestier MV; Doty KR; Town T
    Trends Neurosci; 2015 Nov; 38(11):674-681. PubMed ID: 26549882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Involvement of inflammation in Alzheimer's disease pathogenesis and therapeutic potential of anti-inflammatory agents.
    Shadfar S; Hwang CJ; Lim MS; Choi DY; Hong JT
    Arch Pharm Res; 2015 Dec; 38(12):2106-19. PubMed ID: 26289122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukins, inflammation, and mechanisms of Alzheimer's disease.
    Weisman D; Hakimian E; Ho GJ
    Vitam Horm; 2006; 74():505-30. PubMed ID: 17027528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The contribution of neuroinflammation to amyloid toxicity in Alzheimer's disease.
    Minter MR; Taylor JM; Crack PJ
    J Neurochem; 2016 Feb; 136(3):457-74. PubMed ID: 26509334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroinflammation in Alzheimer's Disease: The Preventive and Therapeutic Potential of Polyphenolic Nutraceuticals.
    Sawikr Y; Yarla NS; Peluso I; Kamal MA; Aliev G; Bishayee A
    Adv Protein Chem Struct Biol; 2017; 108():33-57. PubMed ID: 28427563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic and CNS Inflammation Crosstalk: Implications for Alzheimer's Disease.
    Paouri E; Georgopoulos S
    Curr Alzheimer Res; 2019; 16(6):559-574. PubMed ID: 30907316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Danger-associated molecular patterns in Alzheimer's disease.
    Venegas C; Heneka MT
    J Leukoc Biol; 2017 Jan; 101(1):87-98. PubMed ID: 28049142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic Targets in Innate Immunity to Tackle Alzheimer's Disease.
    Serradas ML; Ding Y; Martorell PV; Kulińska I; Castro-Gomez S
    Cells; 2024 Aug; 13(17):. PubMed ID: 39272998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroinflammation in Alzheimer's disease: from pathogenesis to a therapeutic target.
    Pimplikar SW
    J Clin Immunol; 2014 Jul; 34 Suppl 1():S64-9. PubMed ID: 24711006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SLOH, a carbazole-based fluorophore, mitigates neuropathology and behavioral impairment in the triple-transgenic mouse model of Alzheimer's disease.
    Wu X; Kosaraju J; Zhou W; Tam KY
    Neuropharmacology; 2018 Mar; 131():351-363. PubMed ID: 29309769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Markers of neuroinflammation associated with Alzheimer's disease pathology in older adults.
    Popp J; Oikonomidi A; Tautvydaitė D; Dayon L; Bacher M; Migliavacca E; Henry H; Kirkland R; Severin I; Wojcik J; Bowman GL
    Brain Behav Immun; 2017 May; 62():203-211. PubMed ID: 28161476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel multi-target directed ligand-based strategies for reducing neuroinflammation in Alzheimer's disease.
    Wenzel TJ; Klegeris A
    Life Sci; 2018 Aug; 207():314-322. PubMed ID: 29940242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.